TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20216069

Group type: EXPERIMENTAL
Intervention: Laryngeal tube S II (LTS II)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Laryngeal tube disposable (LTS‐D)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fastrach laryngeal mask (Fastrach)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fastrach laryngeal mask disposable (Fastrach‐D)
Number of subjects: 120
Study: 18521538

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (5-ISMN) 30 mg three times daily for 7 days
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 16240277

Group type: EXPERIMENTAL
Intervention: Perkins tonometer measurements after LASIK
Number of subjects: 125

Group type: COMPARATOR
Intervention: Measured IOP at all set pressure levels
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Correction for measured IOP after LASIK
Number of subjects: 125
Study: 12123336

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 30 microg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 60 microg/kg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 100 microg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: Filgrastim 5 microg/kg/day
Number of subjects: 100
Study: 10561255

Group type: COMPARATOR
Intervention: Interferon alfa‐2a (IFNalpha2a) administered three times weekly at 18 x 10(6) IU
Number of subjects: 113

Group type: COMPARATOR
Intervention: Interleukin‐2 (IL‐2) administered as a continuous intravenous infusion for 5 days (18 x 10(6) IU/m(2)/d)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Cross-over treatment after failure of IL-2 or IFNalpha2a
Number of subjects: 113
Study: 8547958

Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose IL-2 (4.5 million IU/day, 3 times weekly for 6 months)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose IL-2
Number of subjects: 16
Study: 2275355

Group type: EXPERIMENTAL
Intervention: 0.1 sec argon laser trabeculoplasty
Number of subjects: 33

Group type: COMPARATOR
Intervention: 0.2 sec argon laser trabeculoplasty
Number of subjects: 33
Study: 485184

Group type: EXPERIMENTAL
Intervention: PUVA plus betamethasone valerate
Number of subjects: 12

Group type: COMPARATOR
Intervention: PUVA
Number of subjects: 12
Study: 31401971

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 3395

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 3395

Group type: EXPERIMENTAL
Intervention: Carotid stenosis
Number of subjects: 3395

Group type: EXPERIMENTAL
Intervention: Carotid plaque
Number of subjects: 3395
Study: 29972904

Group type: EXPERIMENTAL
Intervention: 65 μm glycine powder air-polishing (GPAP) therapy
Number of subjects: 21

Group type: COMPARATOR
Intervention: Ultrasonic scaling plus polishing paste therapy (Control)
Number of subjects: 21
Study: 26153427

Group type: EXPERIMENTAL
Intervention: BNP-guided treatment
Number of subjects: 0
Study: 23457213

Group type: EXPERIMENTAL
Intervention: ParkFit programme
Number of subjects: 586

Group type: COMPARATOR
Intervention: Matched general physiotherapy intervention (Control)
Number of subjects: 586
Study: 21464041

Group type: EXPERIMENTAL
Intervention: Insulin >6.10 μU/ml
Number of subjects: 2903

Group type: EXPERIMENTAL
Intervention: Insulin <2.75 μU/ml
Number of subjects: 2903

Group type: COMPARATOR
Intervention: Insulin 2.75-4.10 μU/ml
Number of subjects: 2903

Group type: EXPERIMENTAL
Intervention: Insulin >6.10 μU/ml with viral load <4.39 log(10) copies/ml
Number of subjects: 2903

Group type: EXPERIMENTAL
Intervention: Higher insulin levels
Number of subjects: 2903

Group type: COMPARATOR
Intervention: Glucose or diabetes
Number of subjects: 2903
Study: 18262190

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 5783

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5783
Study: 15616086

Group type: EXPERIMENTAL
Intervention: Plantar flexion
Number of subjects: 80

Group type: COMPARATOR
Intervention: Dorsiflexion
Number of subjects: 80
Study: 12394544

Group type: EXPERIMENTAL
Intervention: COMPLETE ComfortPLUS (HPMC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: NO RUB OPTI‐FREE EXPRESS (citrate-based)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both solutions
Number of subjects: 64
Study: 10193067

Group type: EXPERIMENTAL
Intervention: Individual advice (IA)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 170
Study: 7749449

Group type: EXPERIMENTAL
Intervention: Visitor control device (red light to restrict visits, green light to allow visits)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Visitor control device
Number of subjects: 60
Study: 2280167

Group type: EXPERIMENTAL
Intervention: Colored overlay filter (preferred)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Clear overlay filter
Number of subjects: 92

Group type: COMPARATOR
Intervention: Different-colored overlay filters
Number of subjects: 92

Group type: COMPARATOR
Intervention: Nonscotopic children
Number of subjects: 92
Study: 380606

Group type: EXPERIMENTAL
Intervention: Alprenolol 200 mg b.i.d.
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 31683021

Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification (IBM-P)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 31127478

Group type: EXPERIMENTAL
Intervention: Overweight (BMI 24–27.9 kg/m2)
Number of subjects: 5163

Group type: COMPARATOR
Intervention: Normal weight (< 23.9 kg/m2)
Number of subjects: 5163

Group type: EXPERIMENTAL
Intervention: Obese (BMI ≥ 28.0 kg/m2)
Number of subjects: 5163

Group type: EXPERIMENTAL
Intervention: Overweight or Obese
Number of subjects: 5163
Study: 28095787

Group type: EXPERIMENTAL
Intervention: Additional functional training as part of the habitual daily routine during short term stays at nursing homes after discharge from hospital.
Number of subjects: 0
Study: 25588095

Group type: EXPERIMENTAL
Intervention: Medication adherence skills training (MST)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study: 23449357

Group type: EXPERIMENTAL
Intervention: Mf (MMC 20 mg m(‐2), followed by oral doxifluridine 460‐600 mg m(‐2) per day for 3 months)
Number of subjects: 855

Group type: COMPARATOR
Intervention: MFP (MMC 20 mg m(‐2), followed by oral doxifluridine 460‐600 mg m(‐2) per day for 12 months with 6 monthly infusions of 60 mg m(‐2) of cisplatin)
Number of subjects: 855
Study: 21150915

Group type: EXPERIMENTAL
Intervention: Tryptophan (TRP) augmentation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 18808413

Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg biw
Number of subjects: 0

Group type: COMPARATOR
Intervention: No systemic therapy
Number of subjects: 0
Study: 17378197

Group type: EXPERIMENTAL
Intervention: Superficial needling at Sanyinjiao (SP 6)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral administration of indometacin entric-coater tablets
Number of subjects: 120
Study: 14745611

Group type: EXPERIMENTAL
Intervention: Stapled anastomoses (106 anastomoses)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Hand-sewn anastomoses (95 anastomoses)
Number of subjects: 201
Study: 11189794

Group type: EXPERIMENTAL
Intervention: Health education and disease management video games
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Diabetes game
Number of subjects: 2

Group type: COMPARATOR
Intervention: Entertainment video game (control)
Number of subjects: 2
Study: 9894173

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) regimen as studied in ACTG 076
Number of subjects: 0
Study: 8040603

Group type: EXPERIMENTAL
Intervention: 10 g fish oil daily for 3 or 6 months (containing 18% eicosapentaenoic acid and 12% docosahexaenoic acid)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 10 g fish oil daily for 3 or 6 months
Number of subjects: 15
Study: 3055324

Group type: EXPERIMENTAL
Intervention: Tenoretic 100 (atenolol 100 mg; chlorthalidone 25 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Tenoretic 50 (atenolol 50 mg; chlorthalidone 25 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Tenoretic 100 and Tenoretic 50
Number of subjects: 31
Study: 29792052

Group type: EXPERIMENTAL
Intervention: CBT4CBT with brief weekly monitoring
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Clinician-delivered CBT
Number of subjects: 137

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 137
Study: 28816910

Group type: EXPERIMENTAL
Intervention: ADHD group visit model
Number of subjects: 84
Study: 24099551

Group type: EXPERIMENTAL
Intervention: OX219 (5.7/1.4mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Suboxone tablets (8/2mg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Suboxone films
Number of subjects: 100

Group type: COMPARATOR
Intervention: Suboxone tablets and films
Number of subjects: 100
Study: 24025504

Group type: EXPERIMENTAL
Intervention: Docetaxel plus capecitabine (TX)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Docetaxel plus epirubicin (TE)
Number of subjects: 92
Study: 21377898

Group type: EXPERIMENTAL
Intervention: Intradermal vaccine (6 μg hemagglutinin per strain)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Intramuscular vaccine (15 μg hemagglutinin per strain)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Intradermal vaccine
Number of subjects: 85

Group type: COMPARATOR
Intervention: Intramuscular vaccine
Number of subjects: 85
Study: 18163423

Group type: EXPERIMENTAL
Intervention: UMTS at 2140 MHz
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Combined data from adolescents and adults
Number of subjects: 80
Study: 14999442

Group type: EXPERIMENTAL
Intervention: Standard-of-care group (SOC) - all CVCs were changed as planned
Number of subjects: 64

Group type: COMPARATOR
Intervention: Watchful waiting group (WW) - CVCs changed when bacteremia was confirmed or hemodynamic instability occurred
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Standard-of-care group (SOC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Watchful waiting group (WW)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard-of-care group (SOC) and Watchful waiting group (WW)
Number of subjects: 64
Study: 11372588

Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole once daily for 4 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Matched placebo once daily for 4 days
Number of subjects: 12
Study: 9589673

Group type: EXPERIMENTAL
Intervention: Recombinant human GH treatment
Number of subjects: 0
Study: 8303743

Group type: EXPERIMENTAL
Intervention: Stroke unit rehabilitation (younger patients)
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Stroke unit rehabilitation (older patients)
Number of subjects: 245

Group type: COMPARATOR
Intervention: General wards (younger patients)
Number of subjects: 245

Group type: COMPARATOR
Intervention: General wards (older patients)
Number of subjects: 245
Study: 2968185

Group type: EXPERIMENTAL
Intervention: Fentanyl (FEN) 75 micrograms.kg‐1
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Sufentanil (SUF) 15 micrograms.kg‐1
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Alfentanil (ALF) 125 micrograms.kg‐1
Number of subjects: 96
Study: 30336863

Group type: EXPERIMENTAL
Intervention: Laryngeal handshake technique
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional palpation
Number of subjects: 45
Study: 27475670

Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated radiation therapy (MHRT) - 62 Gy in 20 fractions over 5 weeks
Number of subjects: 168

Group type: COMPARATOR
Intervention: Conventional fractionated radiation therapy (CFRT) - 80 Gy in 40 fractions over 8 weeks
Number of subjects: 168
Study: 25431225

Group type: EXPERIMENTAL
Intervention: Qishenyiqi Dripping Pills
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Compound Danshen Dripping Pills
Number of subjects: 144
Study: 22406102

Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 42
Study: 20520854

Group type: EXPERIMENTAL
Intervention: Macrophage Migration Inhibitory Factor (MIF) as a biomarker
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional promoter polymorphisms in the MIF gene
Number of subjects: 0
Study: 18573168

Group type: EXPERIMENTAL
Intervention: Modules with complex cases
Number of subjects: 124

Group type: COMPARATOR
Intervention: Modules without complex cases
Number of subjects: 124
Study: 16925236

Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 59

Group type: COMPARATOR
Intervention: Jejunoileal bypass
Number of subjects: 59
Study: 11818981

Group type: EXPERIMENTAL
Intervention: Paico juice (1 ml/Kg for <10 Kg, 2 ml/Kg for >10 Kg, one dose before breakfast for three consecutive days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Albendazole (400 mg for >5 years, 200 mg for <5 years, single dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Paico juice
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paico and Albendazole
Number of subjects: 60
Study: 10194990

Group type: EXPERIMENTAL
Intervention: Fentanyl infusion (1.1 micrograms/kg/h for 75 hours)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (untreated infants)
Number of subjects: 55
Study: 7917782

Group type: EXPERIMENTAL
Intervention: Proximal site perfusion of paracetamol
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Distal site perfusion of paracetamol
Number of subjects: 4
Study: 3207491

Group type: EXPERIMENTAL
Intervention: Verapamil cardioplegia
Number of subjects: 16

Group type: COMPARATOR
Intervention: Cold cardioplegia without verapamil
Number of subjects: 16
Study: 31547675

Group type: EXPERIMENTAL
Intervention: Soybean meal (SBM)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: High digestibility crude protein (DCP) level (17.2%)
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Rapeseed meal (RSM)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Rapeseed meal (RSM) and maize gluten (MG)
Number of subjects: 288
Study: 30782695

Group type: EXPERIMENTAL
Intervention: New mobile health (mHealth) screen
Number of subjects: 1500

Group type: COMPARATOR
Intervention: Current school hearing screen
Number of subjects: 1500
Study: 29211951

Group type: EXPERIMENTAL
Intervention: 2.6% edathamil gel (Livionex® Dental Gel)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 9
Study: 25266794

Group type: EXPERIMENTAL
Intervention: 0.5 L hydroxyethyl starch 6% 130/0.42 (Group T)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 1 L Ringer's lactate (Group R/L)
Number of subjects: 32
Study: 23510154

Group type: EXPERIMENTAL
Intervention: multicomponent lifestyle intervention (plain milk and enriched milk)
Number of subjects: 108

Group type: COMPARATOR
Intervention: usual diet (control group)
Number of subjects: 108
Study: 22161540

Group type: EXPERIMENTAL
Intervention: ColoPlus® (50 g twice a day for 4 weeks)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard anti-diarrhea treatment alone
Number of subjects: 87
Study: 19244262

Group type: EXPERIMENTAL
Intervention: Vigileo-FloTrac™ system version 1.07
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vigileo-FloTrac™ system version 1.03
Number of subjects: 60
Study: 17115349

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart (BIAsp)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Insulin aspart (IAsp) + human isophane insulin (NPH)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: BIAsp
Number of subjects: 394

Group type: COMPARATOR
Intervention: IAsp + NPH
Number of subjects: 394
Study: 14964505

Group type: EXPERIMENTAL
Intervention: Experimental physical training program (PTP)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Official physical training program (PTP)
Number of subjects: 307
Study: 11530155

Group type: EXPERIMENTAL
Intervention: Culturally-based health promotion programme introduced in 1981, details on dosage and duration not applicable.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control areas without the health promotion programme.
Number of subjects: 0
Study: 9145878

Group type: EXPERIMENTAL
Intervention: Gentamicin 2 mg/kg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Gentamicin 7 mg/kg
Number of subjects: 11
Study: 8198053

Group type: EXPERIMENTAL
Intervention: Vitamin E (900 mg d-alpha-tocopherol/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30194502

Group type: EXPERIMENTAL
Intervention: Combination HIV-prevention and microfinance intervention including HIV-risk reduction, financial-literacy training, vocational training, and a matched-savings program.
Number of subjects: 0
Study: 30236380

Group type: EXPERIMENTAL
Intervention: Hormonal therapy with vigabatrin
Number of subjects: 377

Group type: COMPARATOR
Intervention: Hormonal therapy alone
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Initial control of spasms between days 14 and 42 of treatment
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Increasing lead-time to treatment
Number of subjects: 377
Study: 27772740

Group type: EXPERIMENTAL
Intervention: Prolonged-release fampridine (10mg, twice daily)
Number of subjects: 68
Study: 24474383

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg
Number of subjects: 291
Study: 23306418

Group type: EXPERIMENTAL
Intervention: CoQ10 (200 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 20881069

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg ZnO/d for 5 d/wk)
Number of subjects: 674

Group type: COMPARATOR
Intervention: Placebo (10 mg glucose)
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 674
Study: 18594845

Group type: EXPERIMENTAL
Intervention: 5-FU/oxaliplatin-based chemotherapy (FUFOX vs. CAPOX)
Number of subjects: 108
Study: 16762794

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 6800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6800
Study: 12846707

Group type: EXPERIMENTAL
Intervention: Epidural morphine 0.1 mg.kg‐1 postinduction (EP group, n = 25)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Morphine infusion at 0.02 mg.kg‐1.h‐1 following 0.05 mg.kg‐1 bolus (INF group, n = 25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 50
Study: 11103759

Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate (Seroquel)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 8840904

Group type: EXPERIMENTAL
Intervention: 50 mg naltrexone
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 16
Study: 1539006

Group type: EXPERIMENTAL
Intervention: Involvement of oncology clinical nurse specialists in research
Number of subjects: 0
Study: 6088819

Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg capsules orally five times daily for ten days
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo capsules orally five times daily for ten days
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg capsules
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 150

Group type: COMPARATOR
Intervention: Acyclovir and Placebo
Number of subjects: 150
Study: 31527894

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0
Study: 29018956

Group type: EXPERIMENTAL
Intervention: Kinematic training using virtual reality (VR)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Kinematic training using laser
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study: 27503039

Group type: EXPERIMENTAL
Intervention: 0.2 Hz frequency of latency
Number of subjects: 120

Group type: COMPARATOR
Intervention: 1.0 Hz frequency of latency
Number of subjects: 120
Study: 24549600

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa group (n=86)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Healthy control group (n=21)
Number of subjects: 107
Study: 23147696

Group type: EXPERIMENTAL
Intervention: JTT-751 (1.5 g/day)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: JTT-751 (3 g/day)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: JTT-751 (6 g/day)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 20832440

Group type: EXPERIMENTAL
Intervention: Presence of weight-related cues (body-weight scale) in Study 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Presence of weight-related cues (weight-related verbal statement) in Study 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: No weight-related cues in both studies
Number of subjects: 0
Study: 17526169

Group type: EXPERIMENTAL
Intervention: Liuwei Dihuang Soft Capsule (LDSC) plus Ginkgo Leaf Tablet (GLT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 15321408

Group type: EXPERIMENTAL
Intervention: Sitting posture
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Right hip‐flexed left lateral position
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Left hip‐flexed right lateral position
Number of subjects: 93

Group type: COMPARATOR
Intervention: Supine 30 degrees lateral tilt
Number of subjects: 93
Study: 12521415

Group type: EXPERIMENTAL
Intervention: Outpatient cervical cerclage
Number of subjects: 50

Group type: COMPARATOR
Intervention: Inpatient cervical cerclage
Number of subjects: 50
Study: 9437777

Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin (5.1%, 5/98 positive for C. trachomatis)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Multidose doxycycline (4.1%, 4/98 positive for C. trachomatis)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Multidose therapy compliance (94.5% among 73 women)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Risk factors for persistence or recurrence
Number of subjects: 196
Study: 8591098

Group type: EXPERIMENTAL
Intervention: Fast system response time
Number of subjects: 12

Group type: COMPARATOR
Intervention: Slow system response time
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Delete input numerals
Number of subjects: 12

Group type: COMPARATOR
Intervention: Do not delete input numerals
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Button flashes after input
Number of subjects: 12

Group type: COMPARATOR
Intervention: No button flashes after input
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Remaining time displayed
Number of subjects: 12

Group type: COMPARATOR
Intervention: Remaining time not displayed
Number of subjects: 12